<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To compare the prevalence of <z:mp ids='MP_0002055'>diabetes</z:mp> complications and their risk factors in youth with type 1 versus type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: We performed a comparative clinic-based study of 1,433 patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and 68 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> aged &lt;18 years from New South Wales, Australia </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000488'>Retinopathy</z:hpo> was assessed by seven-field stereoscopic <z:chebi fb="46" ids="15035">retinal</z:chebi> photography; albumin excretion rate from three consecutive, timed, overnight urine collections; <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> by thermal and vibration threshold; and <z:e sem="disease" ids="C0259749" disease_type="Disease or Syndrome" abbrv="">autonomic neuropathy</z:e> by pupillometry </plain></SENT>
<SENT sid="3" pm="."><plain>HbA(1c) (A1C) and <z:chebi fb="23" ids="18059">lipids</z:chebi> were measured in <z:hpo ids='HP_0000001'>all</z:hpo> patients and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In patients with type 1 versus type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, median (interquartile range) age was 15.7 years (13.9-17.0) and 15.3 years (13.6-16.4), respectively (P = 0.2), whereas median <z:mp ids='MP_0002055'>diabetes</z:mp> duration was 6.8 years (4.7-9.6) and 1.3 years (0.6-3.1), respectively (P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000488'>Retinopathy</z:hpo> was significantly more common in patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> (20 vs. 4%, P = 0.04), while <z:mp ids='MP_0002959'>microalbuminuria</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> were significantly less common (6 and 16% in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> vs. 28 and 36% in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) </plain></SENT>
<SENT sid="6" pm="."><plain>Rates of peripheral and <z:e sem="disease" ids="C0259749" disease_type="Disease or Syndrome" abbrv="">autonomic neuropathy</z:e> were similar (27 and 61% in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> vs. 21 and 57% in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) </plain></SENT>
<SENT sid="7" pm="."><plain>In multivariate analyses, <z:mp ids='MP_0002959'>microalbuminuria</z:mp> was significantly associated with older age (odds ratio 1.3 [95% CI 1.2-1.5], P &lt; 0.001) and systolic <z:hpo ids='HP_0000822'>hypertension</z:hpo> (3.63 [2.0-6.3], P &lt; 0.001) in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, while only higher A1C (1.7 [1.3-2.9], P = 0.002) was significant in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Youth with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have significantly higher rates of <z:mp ids='MP_0002959'>microalbuminuria</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> than their peers with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, despite shorter <z:mp ids='MP_0002055'>diabetes</z:mp> duration and lower A1C </plain></SENT>
<SENT sid="9" pm="."><plain>The results of this study support recommendations for early complications screening and aggressive targeting of glycemic control in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>